The Application of Probiotics in the Improvement of Metabolic Syndrome

Abstract

Metabolic syndrome (MetS) clusters central obesity, dysglycaemia, atherogenic dyslipidaemia and hypertension, and its rising global prevalence demands innovative preventive strategies. This narrative review critically examines the tri-directional interplay between probiotics, gut microbiota and host metabolism, and evaluates whether targeted live-microbe interventions can serve as a safe, low-cost adjunct to standard care. The progression from early animal observations to recent multicentre human trials is traced, and evidence that select lactobacilli, bifidobacteria and next-generation commensals modulate short-chain-fatty-acid signalling, bile-acid metabolism and mucosal immunity, thereby simultaneously improving insulin sensitivity, lipid profile and low-grade inflammation, is consolidated. Particular attention is given to strain-specific functionalities, the influence of baseline microbiota and diet, and the conceptual shift from universal supplementation to precision formulations. Current limitations, including short follow-up, small sample sizes and absence of hard clinical end-points—are discussed, and a roadmap for future large-scale, endpoint-driven studies is proposed. Overall, mechanistic and clinical findings converge to support the integration of tailored probiotics into comprehensive MetS management, but translational success will require multidisciplinary collaboration, standardized manufacturing and personalized algorithms.